Today’s Market Runner: Is Selling MacroGenics Inc Here a Winning Strategy?

Today's Market Runner: Is Selling MacroGenics Inc Here a Winning Strategy?

The stock of MacroGenics Inc (NASDAQ:MGNX) is a huge mover today! About 131,491 shares traded hands. MacroGenics Inc (NASDAQ:MGNX) has risen 70.28% since March 9, 2016 and is uptrending. It has outperformed by 62.87% the S&P500.
The move comes after 7 months negative chart setup for the $905.46 million company. It was reported on Oct, 12 by We have $25.36 PT which if reached, will make NASDAQ:MGNX worth $63.38M less.

Analysts await MacroGenics Inc (NASDAQ:MGNX) to report earnings on November, 2. They expect $-0.84 EPS, down 82.61% or $0.38 from last year’s $-0.46 per share. After $1.12 actual EPS reported by MacroGenics Inc for the previous quarter, Wall Street now forecasts -175.00% negative EPS growth.

MacroGenics Inc (NASDAQ:MGNX) Ratings Coverage

Out of 4 analysts covering MacroGenics (NASDAQ:MGNX), 2 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 50% are positive. MacroGenics has been the topic of 8 analyst reports since August 6, 2015 according to StockzIntelligence Inc. As per Thursday, August 6, the company rating was maintained by Stifel Nicolaus. The stock of MacroGenics Inc (NASDAQ:MGNX) earned “Neutral” rating by Citigroup on Thursday, August 4. On Thursday, February 25 the stock rating was initiated by Morgan Stanley with “Equal-Weight”. The rating was initiated by Janney Capital on Thursday, February 18 with “Buy”. The firm has “Buy” rating given on Monday, October 19 by Citigroup. Citigroup initiated the stock with “Neutral” rating in Thursday, September 17 report. As per Monday, August 10, the company rating was downgraded by Zacks.

According to Zacks Investment Research, “MacroGenics Inc. is a biopharmaceutical company. It is focused on discovering and developing innovative monoclonal antibody-based therapeutics. The Company has a diverse portfolio of product candidates focused in three therapeutic areas: oncology, autoimmune disorders and infectious diseases. MacroGenics Inc. is headquartered in Rockville, Maryland.”

Insitutional Activity: The institutional sentiment decreased to 1.21 in Q2 2016. Its down 0.17, from 1.38 in 2016Q1. The ratio is negative, as 14 funds sold all MacroGenics Inc shares owned while 34 reduced positions. 13 funds bought stakes while 45 increased positions. They now own 27.76 million shares or 2.47% less from 28.46 million shares in 2016Q1.
Suffolk Capital Mngmt Ltd Liability accumulated 0.2% or 58,010 shares. Oxford Asset Mngmt, a United Kingdom-based fund reported 96,417 shares. Blackrock Group Ltd last reported 8,833 shares in the company. Great West Life Assurance Can holds 0% of its portfolio in MacroGenics Inc (NASDAQ:MGNX) for 2,500 shares. Jennison Assocs Ltd Liability holds 196,162 shares or 0.01% of its portfolio. Rhumbline Advisers holds 0% or 33,113 shares in its portfolio. Tocqueville Asset Limited Partnership last reported 0.01% of its portfolio in the stock. Mpm Asset Mgmt Ltd Company has invested 0.03% of its portfolio in MacroGenics Inc (NASDAQ:MGNX). Mufg Americas Hldgs Corporation holds 0% of its portfolio in MacroGenics Inc (NASDAQ:MGNX) for 180 shares. Ubs Asset Management Americas has 0.02% invested in the company for 556,344 shares. Schwab Charles Invest Management accumulated 114,901 shares or 0% of the stock. Baker Bros Advisors Lp accumulated 363,676 shares or 0.1% of the stock. Jpmorgan Chase has 218,891 shares for 0% of their US portfolio. Gam Ag holds 0.03% of its portfolio in MacroGenics Inc (NASDAQ:MGNX) for 77,800 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0% or 1,270 shares in its portfolio.

Insider Transactions: Since May 27, 2016, the stock had 0 insider purchases, and 6 sales for $1.60 million net activity. Cilinski Lynn had sold 8,922 shares worth $242,857 on Friday, July 1. $136,100 worth of shares were sold by Wigginton Jon Marc on Friday, July 1.

More notable recent MacroGenics Inc (NASDAQ:MGNX) news were published by: which released: “/quotes/zigman/3870025/realtime” on November 04, 2013, also with their article: “MacroGenics Enters Collaboration and License Agreement with Janssen to Develop …” published on May 18, 2016, published: “MacroGenics begins expansion following $141M round” on August 14, 2015. More interesting news about MacroGenics Inc (NASDAQ:MGNX) were released by: and their article: “Japanese drugmaker drops deal for a key MacroGenics drug” published on September 13, 2016 as well as‘s news article titled: “MacroGenics to Present at the Leerink Partners Rare Disease & Immuno-Oncology …” with publication date: September 23, 2016.

MGNX Company Profile

MacroGenics, Inc., incorporated on August 14, 2000, is a clinical-stage biopharmaceutical firm focused on discovering and developing monoclonal antibody therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Firm operates through developing monoclonal antibody therapeutics for cancer, autoimmune and infectious diseases segment. The Firm develops therapeutic product candidates using its antibody technology platforms and in partnership with other biopharmaceutical companies. The Firm has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created primarily using its technology platforms.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment